Cargando…
P1530: PERITRANFUSIONAL C1-INHIBITOR IN PATIENTS WITH SEVERE COMPLEMENT-MEDIATED AUTOIMMUNE HEMOLYTIC ANEMIA: AN OPEN LABEL PHASE 2 TRIAL.
Autores principales: | de Boer, E. C. W., Jalink, M., Delvasto-Nuñes, L., Meulenbroek, E. M., Baas, I., Janssen, S. R., Dijkman, E. E., Gelderman, K. A., Wouters, D., Engel, M. D., de Haas, M., Kersten, M.-J., Jongerius, I., Zeerleder, S., Vos, J. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430584/ http://dx.doi.org/10.1097/01.HS9.0000848976.85981.b3 |
Ejemplares similares
-
C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia
por: de Boer, Esther C. W., et al.
Publicado: (2023) -
Halting targeted and collateral damage to red blood cells by the complement system
por: Jalink, M., et al.
Publicado: (2021) -
Inclusive XI0, XI(1530)- and XI(1530)0 production in XI- Be interactions at 116 GeV/c
por: Schneider, O, et al.
Publicado: (1989) -
Painting in Britain, 1530-1790
por: Waterhouse, Ellis Kirkham, 1905-
Publicado: (1953) -
The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation
por: de Boer, Esther CW, et al.
Publicado: (2023)